AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 3.
Thomson Scientific, 77 Hatton Garden, London, EC1N 8JS, UK. tracey.collins@thomson.com
Tracey
T
Collins
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002868:Chromosomal Proteins, Non-Histone / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D016503:Drug Delivery Systems; D006801:Humans; D008081:Liposomes; D009369:Neoplasms / Q000188:drug therapy*; D036104:Receptor, EphA2 / Q000037:antagonists & inhibitors; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000037:antagonists & inhibitors; D059004:Topoisomerase I Inhibitors
D000970:Antineoplastic Agents; D002868:Chromosomal Proteins, Non-Histone; D008081:Liposomes; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D059004:Topoisomerase I Inhibitors; C068688:centromere protein E; D036104:Receptor, EphA2; D018844:Cyclin-Dependent Kinases